Evaluating human papillomavirus vaccination programs

被引:282
作者
Taira, AV
Neukermans, CP
Sanders, GD
机构
[1] Duke Univ, Duke Clin Res Inst, Durham, NC 27715 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
D O I
10.3201/eid1011.040222
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated vaccination programs with a vaccine against HPV-16 and HPV-18. We developed disease transmission models that estimated HPV prevalence and infection rates for the population overall, by age group, by level of sexual activity within each age group, and by sex. Data were based on clinical trials and published and unpublished sources. An HPV-16/18 vaccine for 12-year-old girls would reduce cohort cervical cancer cases by 61.8%, with a cost-effectiveness ratio of $14,583 per quality-adjusted life year (QALY). Including male participants in a vaccine rollout would further reduce cervical cancer cases by 2.2% at an incremental cost-effectiveness ratio of $442,039/QALY compared to female-only vaccination. Vaccination against HPV-16 and HPV-18 can be cost-effective, although including male participants in a vaccination program is generally not cost-effective, compared to female-only vaccination.
引用
收藏
页码:1915 / 1923
页数:9
相关论文
共 54 条
[1]  
[Anonymous], SOCIAL ORG SEXUALITY
[2]   DETERMINANTS OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION IN LOW-RISK WOMEN IN PORTLAND, OREGON [J].
BAUER, HM ;
HILDESHEIM, A ;
SCHIFFMAN, MH ;
GLASS, AG ;
RUSH, BB ;
SCOTT, DR ;
CADELL, DM ;
KURMAN, RJ ;
MANOS, MM .
SEXUALLY TRANSMITTED DISEASES, 1993, 20 (05) :274-278
[3]  
BERNSTEIN AB, 1991, MED CARE, V29, P196
[4]   Mathematical models of disease transmission: A precious tool for the study of sexually transmitted diseases [J].
Boily, MC ;
Masse, B .
CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 1997, 88 (04) :255-265
[5]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[6]   Human papillomavirus vaccines [J].
Breitburd, F ;
Coursaget, P .
SEMINARS IN CANCER BIOLOGY, 1999, 9 (06) :431-445
[7]   Economic evaluation of vaccination programs: The impact of herd-immunity [J].
Brisson, M ;
Edmunds, WJ .
MEDICAL DECISION MAKING, 2003, 23 (01) :76-82
[8]   Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing [J].
Brown, AD ;
Garber, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (04) :347-353
[9]   Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina [J].
Clements, DA ;
Zaref, JI ;
Bland, CL ;
Walter, EB ;
Coplan, PM .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2001, 155 (04) :455-461
[10]  
DAGAN R, 2002, NATL HEPATITIS A VAC